Ask about this productRelated genes to: CYP2D6 antibody
- Gene:
- CYP2D6 NIH gene
- Name:
- cytochrome P450 family 2 subfamily D member 6
- Previous symbol:
- CYP2DL1, CYP2D7P2, CYP2D7BP, CYP2D8P2, CYP2D7AP
- Synonyms:
- CPD6, P450-DB1, CYP2D, P450C2D
- Chromosome:
- 22q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-07
- Date modifiied:
- 2019-04-23
Related products to: CYP2D6 antibody
Related articles to: CYP2D6 antibody
- Pharmacogenetics (PGx) has traditionally focused on a small number of high-impact variants affecting drug response due to the fact that PGx studies are labor-intensive and therefore low-throughput. Population biobanks linked to electronic health records (EHRs), including the UK Biobank (UKB) with prescription data for ~ 230,000 individuals offer opportunities to scale PGx research. This, however, comes with a challenge as EHRs do not provide direct treatment response outcomes. One way to overcome this is to draw indirect drug response phenotypes from prescription records. - Source: PubMed
Publication date: 2026/08/24
Pieczarka MariaPieńkowski PawełKonowalska PaulaGrubarek SylwiaHajto JacekHoinkis DżesikaPiechota MarcinBorczyk MałgorzataKorostyński Michał - This study quantified age-related differences in fluoxetine pharmacokinetics and evaluated the influence of CYP2D6 phenotype using physiologically based pharmacokinetic (PBPK) modeling integrated with clinical therapeutic drug monitoring data. A PBPK model for fluoxetine and its active metabolite norfluoxetine was implemented in the Simcyp Simulator and verified using published pharmacokinetic studies. Simulations of repeated fluoxetine administration (20 mg once daily) were performed in younger adults (18-65 years) and elderly individuals (65-98 years). Model predictions were compared with therapeutic drug monitoring data from Korean 47 patients (18-88 years) receiving fluoxetine for at least 5 weeks. Simulations demonstrated delayed steady-state attainment and reduced clearance in elderly individuals, resulting in approximately two-fold higher fluoxetine exposure after prolonged dosing and 1.5-fold higher total active moiety exposure than in younger adults. Clinical observations supported these findings, with significantly higher dose-normalized trough concentrations in elderly patients. Although CYP2D6 phenotype affected parent-drug exposure, total active moiety exposure varied only modestly across phenotypes, suggesting that CYP2D6 phenotyping may not be necessary when titrating fluoxetine doses in elderly patients. These findings demonstrate that aging may enhance fluoxetine accumulation during chronic therapy, supporting cautious dose titration and extended monitoring in the elderly population. - Source: PubMed
Jang Yoo JinHeo Dong-GyuHong Eunjin - This narrative review critically assesses the clinical relevance of pharmacogenomics within dental genomics, distinguishing clinically actionable applications from emerging or investigational findings. - Source: PubMed
Publication date: 2026/08/21
Pieretto GiorgiaCusato JessicaSansavini MartinaBacci Christian - Cytochrome P450 2D6 (CYP2D6) is a polymorphic enzyme that influences antidepressant metabolism. This retrospective cohort study investigated the association between CYP2D6 genotype and treatment outcomes in 99 hospitalized patients with major depressive disorder (MDD) in Belgrade, Serbia. Patients were classified as poor (PM, n = 5), intermediate (IM, n = 21), or normal metabolizers (NM, n = 73). Effectiveness and tolerability were assessed from admission to discharge (~4 weeks). Hamilton Depression Rating Scale (HAM-D) score reduction was the primary outcome; tolerability was measured using the Toronto Side Effects Scale (TSES). Compared with NMs, HAM-D score reductions were 4.3 and 9.0 points lower in IMs and PMs. TSES scores were 1.3 and 2.3 points higher in IMs and PMs, respectively. Central nervous system and gastrointestinal effects were more frequent in IMs and PMs; sexual dysfunction did not differ. Reduced CYP2D6 activity was associated with poorer outcomes, indicating the potential usefulness of CYP2D6 genotyping in MDD. - Source: PubMed
Publication date: 2026/08/19
Petković Ćurčin AleksandraJeremić AleksandraJoković DaniloŠupić GordanaSimić KatarinaMilosavljević FilipStojanović ZvezdanaJukić Marin M - INTRODUCTION : The evaluation of pharmacokinetic interactions is based on the knowledge of enzymatic metabolization by cytochrome 450 enzymes or cellular transport processes. Research on the metabolism of pipamperone, an antipsychotic of the butyrophenone family, has not yet yielded conclusive results. In the present in vitro study, human cytochrome enzymes were investigated for their possible involvement in the metabolism of pipamperone. - Source: PubMed
Publication date: 2026/08/19
Pfaff TamaraHinz BurkhardWalther Udo I